Drugs Made In America Acquisition Corp. (DMAA) · Oct 21, 2026 · Material agreement
$1.71B fallback valuation — $1.71B standalone versus $2.85B with APQC and UltraSolar
DMAA amended its merger with PAGC, adding a lower standalone valuation if APQC does not close while a new fairness opinion remains pending.
PAGC is the operating business DMAA is trying to take public: an AI, advanced-analytics and quantum-resistant security company. The amendment changes the deal from a single high-value outcome tied to APQC and UltraSolar into a two-track structure.
The transaction now has a workable fallback, but at a steeply lower valuation. The existing deal valued PAGC at $2.85 billion including APQC and the UltraSolar intellectual property; the amendment automatically reduces that to $1.71 billion if a Reversion Event occurs. That is a 40% haircut, but it removes the requirement that APQC close before DMAA can proceed. The standalone valuation covers only PAGC’s assets and intellectual property owned as of October 13, 2026. 〔0〕
| Deal element | Existing terms | Amendment |
|---|---|---|
| Closing valuation including APQC and UltraSolar | $2.85 billion | Remains available if APQC closes without a Reversion Event |
| Standalone PAGC valuation | Not applicable | $1.71 billion |
| Merger consideration | Shares at the Reference Price | Shares at the Reference Price, with no earnout or contingent consideration |
| Fairness opinion | Prior firm engagement ended October 2, 2026 | Joel A. Gallo engaged October 12; expected by October 26, 2026 |
The immediate hurdle is still the fairness opinion, not the valuation mechanics. The original independent firm terminated its engagement after determining that the intellectual-property assignment required an additional evaluator. DMAA has now hired a sole-practitioner evaluator who says he can value the intellectual property, but the opinion is not yet delivered and remains a closing condition. 〔1〕
This is a meaningful process repair, not a clean deal de-risking. If APQC cannot be completed, DMAA no longer has to terminate solely because that condition failed, but shareholders would be asked to approve a transaction based on a much lower asset set and valuation. Any later increase requires another written amendment and supplemental fairness opinion, so the amendment limits the ability to shift assets into the deal informally.
Bottom line: DMAA has made the merger more executable by creating a $1.71 billion PAGC-only path, but it gives up substantial headline value if APQC does not land. The next decisive proof point is whether the replacement fairness opinion supports closing.
Fairness opinion expected by October 26, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!